Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pomalidomide plus low‐dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure

Published:2019-10-06 Issue:4 Volume:188 Page:501-510
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Siegel David S.¹^ORCID,Schiller Gary J.²,Song Kevin W.³,Agajanian Richy⁴,Stockerl‐Goldstein Keith⁵,Kaya Hakan⁶,Sebag Michael⁷,Samaras Christy⁸,Malek Ehsan⁹,Talamo Giampaolo¹⁰,Seet Christopher S.²,Mouro Jorge¹¹,Pierceall William E.¹¹,Zafar Faiza¹¹,Chung Weiyuan¹¹,Srinivasan Shankar¹¹,Agarwal Amit¹¹,Bahlis Nizar J.¹²

Affiliation:

1. John Theurer Cancer Center Hackensack University Medical Center Hackensack NJ USA

2. David Geffen School of Medicine at UCLA Los Angeles CA USA

3. Vancouver General Hospital Vancouver BC Canada

4. The Oncology Institute of Hope and Innovation Downey CA USA

5. Washington University School of Medicine St. Louis MO USA

6. Cancer Care Northwest Spokane WA USA

7. McGill University Health Centre Montreal QC Canada

8. Cleveland Clinic Cleveland OH USA

9. University Hospitals Case Medical Center Cleveland OH USA

10. Penn State Hershey Cancer Institute Hershey PA USA

11. Celgene Corporation Summit NJ USA

12. University of Calgary Calgary AB Canada

Funder

Celgene

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16213

Reference38 articles.

1. Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma

2. Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

3. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

4. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

5. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece;Clinical Lymphoma Myeloma and Leukemia;2024-07

3. From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation;Annual Review of Pharmacology and Toxicology;2024-01-23

4. Risk of thromboembolic events associated with different multiple myeloma regimens in Taiwan: a nested case-control study;Journal of Thrombosis and Thrombolysis;2023-09-22

5. Cellular immunity in the era of modern multiple myeloma therapy;International Journal of Cancer;2023-06-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3